Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
Status unconfirmed · Phase 2
Conditions studied: Melanoma
In brief
Tesetaxel is an orally administered chemotherapy agent of the taxane class. This study is being undertaken to evaluate the efficacy and safety of tesetaxel administered as second-line therapy to patients with advanced melanoma and normal serum lactate dehydrogenase (LDH).
Key facts
- Study ID
- NCT01092585
- Run by
- Genta Incorporated
- People needed
- 27
- Starts
- 2010-02-01
- Expected to finish
- 2012-03-01
- Last updated by the study team
- 2011-11-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.